Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral paricalcitol.

Emma D Deeks1, Katherine A Lyseng-Williamson

  • 1Adis International Inc., Yardley, Pennsylvania, USA.

Treatments in Endocrinology
|September 28, 2006
PubMed
Summary
This summary is machine-generated.

Oral paricalcitol effectively treats secondary hyperparathyroidism in chronic kidney disease patients. This vitamin D analog significantly reduced parathyroid hormone levels and bone turnover markers with good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Abrocitinib: First Approval.

Drugs·2022
Same author

Asciminib: First Approval.

Drugs·2022
Same author

Chiglitazar: First Approval.

Drugs·2021
Same author

Atogepant: First Approval.

Drugs·2021
Same author

Abrocitinib: First Approval.

Drugs·2021
Same author

Casirivimab/Imdevimab: First Approval.

Drugs·2021
Same journal

The replacement of human insulin with insulin analogs: a survey conducted in france to determine current and recommended practice.

Treatments in endocrinology·2006
Same journal

Is there a rationale for insulin therapy in pre-diabetic individuals?

Treatments in endocrinology·2006
Same journal

Optimizing the benefits of bisphosphonates in osteoporosis : the importance of appropriate calcium intake.

Treatments in endocrinology·2006
Same journal

Is bio-identical hormone replacement therapy safer than traditional hormone replacement therapy?: a critical appraisal of cardiovascular risks in menopausal women.

Treatments in endocrinology·2006
Same journal

A review of transdermal hormonal contraception : focus on the ethinylestradiol/norelgestromin contraceptive patch.

Treatments in endocrinology·2006
Same journal

Anabolic Agents for Osteoporosis : What is Their Likely Place in Therapy?

Treatments in endocrinology·2006
See all related articles

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Secondary hyperparathyroidism is common in chronic kidney disease (CKD) stages 3-4.
  • Vitamin D analogs are crucial for managing this condition.

Purpose of the Study:

  • To evaluate the efficacy and safety of an oral paricalcitol formulation.
  • To assess its impact on parathyroid hormone (PTH) and bone turnover markers.

Main Methods:

  • Pooled analysis of three 24-week randomized, placebo-controlled trials.
  • Assessed reduction in intact PTH levels and biochemical bone markers.
  • Monitored for hypercalcemia, hyperphosphatemia, and elevated calcium-phosphorus product.

Main Results:

Related Experiment Videos

  • Oral paricalcitol achieved significant PTH reduction (91% vs 13% for placebo).
  • Reduced bone turnover markers (serum bone-specific alkaline phosphatase, osteocalcin, urinary pyridinoline).
  • No significant difference in adverse events like hypercalcemia compared to placebo.

    • Conclusions:

    • Oral paricalcitol is an effective treatment for secondary hyperparathyroidism in CKD stages 3-4.
    • It demonstrates favorable safety and tolerability profiles.
    • This formulation offers a viable therapeutic option for managing CKD-mineral and bone disorder.